Maravai LifeSciences Holdings (Maravai LifeSciences Holdings) COGS-to-Revenue : 0.47 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Maravai LifeSciences Holdings COGS-to-Revenue?

Maravai LifeSciences Holdings's Cost of Goods Sold for the three months ended in Dec. 2023 was $35.1 Mil. Its Revenue for the three months ended in Dec. 2023 was $74.1 Mil.

Maravai LifeSciences Holdings's COGS to Revenue for the three months ended in Dec. 2023 was 0.47.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Maravai LifeSciences Holdings's Gross Margin % for the three months ended in Dec. 2023 was 52.65%.

Maravai LifeSciences Holdings COGS-to-Revenue Historical Data

The historical data trend for Maravai LifeSciences Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maravai LifeSciences Holdings COGS-to-Revenue Chart

Maravai LifeSciences Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.47

0.28

0.18

0.19

0.51

Maravai LifeSciences Holdings Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial														0.26	0.43	0.63	0.55	0.47

Maravai LifeSciences Holdings COGS-to-Revenue Calculation

Maravai LifeSciences Holdings's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	148.743	/	288.945
	=	0.51

Maravai LifeSciences Holdings's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	35.108	/	74.141
	=	0.47

Maravai LifeSciences Holdings (NAS:MRVI) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Maravai LifeSciences Holdings's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	35.108 / 74.141
	=	52.65 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Maravai LifeSciences Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Maravai LifeSciences Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Maravai LifeSciences Holdings (Maravai LifeSciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maravai LifeSciences Holdings Inc (NAS:MRVI) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

MRVI:Mexico MAR:Germany

Address

10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121

Website

https://www.maravai.com

Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Executives

John A Deford	director	C R BARD INC, 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Rebecca Buzzeo	officer: See Remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Andrew Burch	officer: See Remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Martin William E. Iii	officer: See remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Peter Michael Leddy	officer: See Remarks	1620 FARADAY AVE, CARLSBAD CA 92008
Carl Hull	director, officer: Chief Executive Officer	300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Gregory T Lucier	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kurt Oreshack	officer: General Counsel	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Murali Prahalad	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Lisa Sellers	officer: See Remarks	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Susannah Gray	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Robert B Hance	director	300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Jessica Hopfield	director	C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Brian Neel	officer: See Remarks	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Christine Dolan	officer: See Remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121